Overview
Chronic Epstein-Barr virus (EBV) infection syndrome, particularly in its lethal form known as chronic active EBV infection (CAEBV), encompasses a spectrum of disorders ranging from mild to severe, including multiple organ failure, hemophagocytic syndrome, and lymphoma development 1.Diagnosis
Clinical presentation includes persistent fever, hepatosplenomegaly, cytopenias, and organ dysfunction 1.
Laboratory findings often reveal elevated EBV DNA levels in blood or tissues 1.
Histopathological evidence of EBV-infected cells in affected organs is crucial 1.
Specific EBV serology and PCR testing for viral load are recommended 1.Management
First-line treatments: Antiviral agents (e.g., ganciclovir) and immunomodulatory therapies (e.g., corticosteroids) are typically used initially 1.
Adjunctive treatments: Rituximab, an anti-CD20 monoclonal antibody, may be considered for B-cell depletion in refractory cases 1.
Curative approach: Allogeneic nonmyeloablative stem cell transplantation (allo-NST) can be effective in refractory cases, especially when conventional therapies fail 1.Special Populations
Pediatrics: Allogeneic nonmyeloablative stem cell transplantation has shown efficacy in adolescents with lethal CAEBV 1.
Comorbidities: Patients with multiple organ dysfunction may require tailored, less toxic regimens like allo-NST to avoid regimen-related toxicities 1.Key Recommendations
Consider allogeneic nonmyeloablative stem cell transplantation for patients with lethal CAEBV who are refractory to conventional therapies and have significant comorbidities (Evidence: Moderate) 1.
Monitor EBV DNA levels and specific cytotoxic T lymphocyte activity post-transplantation to assess immune reconstitution (Evidence: Expert opinion) 1.
Prioritize supportive care and immunomodulatory therapies in managing symptoms and preventing complications in CAEBV patients (Evidence: Moderate) 1.References
1 Uehara T, Nakaseko C, Hara S, Harima A, Ejiri M, Yokota A et al.. Successful control of Epstein-Barr virus (EBV)-infected cells by allogeneic nonmyeloablative stem cell transplantation in a patient with the lethal form of chronic active EBV infection. American journal of hematology 2004. link